TheraRadar
← Back
Data updated: Nov 8, 2026

ALICORA

Generics

ALICORA is a generic drug manufacturer focused on Neurology.

2012
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

ALICORA's Key Drugs

ALICORA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ALICORA's Recent FDA Approvals

New NDA/BLA approvals for ALICORA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALICORA's Therapeutic Areas

ALICORA's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

ALICORA's Top Competitors

ALICORA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ALICORA Pipeline Snapshot

Active clinical trials for ALICORA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling